In addition, preclinical data investigating combinational approaches has demonstrated that dasatinib sensitizes KRAS mutant CRC tumors to anti-EGFR therapy in vitro and in vivo, suggesting that there may be additional biomarker data yet to be fully elucidated to help drive future studies [35]. Here, KRAS is linked to colorectal carcinoma.